Media headlines about Aratana Therapeutics (NASDAQ:PETX) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aratana Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 47.0953335408086 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
A number of equities analysts recently commented on the company. ValuEngine downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. BidaskClub downgraded Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Lake Street Capital dropped their price objective on Aratana Therapeutics from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Friday, August 25th. Jefferies Group LLC set a $8.00 price objective on Aratana Therapeutics and gave the stock a “buy” rating in a report on Friday, August 4th. Finally, Zacks Investment Research upgraded Aratana Therapeutics from a “hold” rating to a “buy” rating and set a $8.00 price objective on the stock in a report on Tuesday, July 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. Aratana Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $8.25.
Aratana Therapeutics (NASDAQ:PETX) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.03. Aratana Therapeutics had a negative return on equity of 51.21% and a negative net margin of 642.93%. The company had revenue of $5.16 million for the quarter, compared to analysts’ expectations of $4.50 million. During the same quarter in the prior year, the business posted $0.61 EPS. The business’s revenue was down 86.4% compared to the same quarter last year.
In other news, COO Brent Standridge sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $6.11, for a total transaction of $61,100.00. Following the sale, the chief operating officer now owns 70,267 shares in the company, valued at approximately $429,331.37. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Peter Steven St sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $6.24, for a total value of $312,000.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 70,000 shares of company stock worth $435,600. Company insiders own 5.20% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/2956954/aratana-therapeutics-petx-receiving-somewhat-positive-press-coverage-study-shows.html.
About Aratana Therapeutics
Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.
Receive News & Ratings for Aratana Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.